Brief: Trevi Therapeutics Reports Notice Of Allowance For U.S. Patent Application Covering Use Of Haduvio (nalbuphine ER)
08/03/2023 12:46
March 8 (Reuters) - Trevi Therapeutics Inc TRVI.O :
* TREVI THERAPEUTICS ANNOUNCES NOTICE OF ALLOWANCE FOR U.S.
PATENT
APPLICATION COVERING USE OF HADUVIO™ (NALBUPHINE ER) FOR THE
TREATMENT OF CHRONIC COUGH IN IDIOPATHIC PULMONARY FIBROSIS
* TREVI THERAPEUTICS INC - EXPECTS THE RESULTING PATENT WILL
BE
ORANGE BOOK-LISTABLE WITH AN ANTICIPATED EXPIRATION IN 2039
Source text for Eikon: ID:nPnbgjCtga
Further company coverage: TRVI.O
Recent news on Trevi Therapeutics
See all newsTrevi Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Trevi Therapeutics Q2 net loss widens on higher R&D costs
Brief: Trevi Therapeutics Q2 Net Income USD -17.797 Million
Trevi Therapeutics Q1 net loss widens as R&D costs rise
Brief: Trevi Therapeutics Q1 Net Income USD -13.192 Million